Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment The FIELD Study
Ru-Dee Ting, Anthony C Keech, Paul L Drury, Mark W Donoghoe, John Hedley, Alicia J Jenkins, Timothy ME Davis, Seppo Lehto, David Celermajer, R John Simes, Kushwin Rajamani, Kim Stanton
Diabetes Care | AMER DIABETES ASSOC | Published : 2012
The FIELD Study was supported by grants from Laboratoires Fournier SA, Dijon, France (now part of Abbott Pharmaceuticals), and the National Health and Medical Research Council (NHMRC) of Australia.R.-D.T., A.C.K., T.M.E.D., R.J.S., and K.R. have received speaker's bureau fees from Solvay (now Abbott Pharmaceuticals). A.C.K., P.L.D., A.J.J., T.M.E.D., and R.J.S. have received travel and/or research grant support from Solvay (now Abbott Pharmaceuticals). No other potential conflicts of interest relevant to this article were reported.